Supreme Court limits scope of review of Myriad to eligibility Dec. 4, 2012 By Mark McCarty The Supreme Court has opted to take the Myriad gene patent case, the outcome of which could fundamentally alter how life science companies draft patents for inventions involving genetic materials. Read More
Washington roundup: CMS eyes coverage review for dozens of products, procedures Dec. 4, 2012 By Mark McCarty
RSS